Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

Principal investigator of the PRECISE Trial, Dr Pamela Douglas (Duke University School of Medicine, NC) joins late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the trial design and latest data.


The rationale of the PRECISE trial was to evaluate if a precision approach of coronary-CTA-led diagnostic pathways tailored to patient risk improved clinical outcomes in patients with CAD as compared to usual care. Patients in the "precision evaluation strategy" arm with elevated risk were assessed based on pretest clinical characteristics using the PROMISE risk tool.

Recorded remotely from North Carolina and California, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "AHA 22 Late-Breaker Discussion: The PRECISE Trial" передвинте ползунок вправо